What's happening
Live detector signal
Generated 19:59 ET
SLXN — Silexion Therapeutics Corp Ordinary Shares is down 18.1%, at 0.35, on $774.4K traded, 0.58× float rotation. Score 74. Primary driver: 58.1% float rotation. Supply intelligence: squeeze-prone · 86.
Get alerts on $SLXN
Halts, resumptions, new filings, and updated reports — in your inbox within minutes of the event.
Free · one email per event, no digests or spam · unsubscribe anytime · joins real followers
Free float
3.9M
2026-08-13
Shares out
5.8M
latest detail
Market cap
$2.4M
at ref price
Short interest
0.4%
2026-08-31
Float rotation
0.58×
latest snapshot
20d dollar vol
$2.7M
baseline
Gap quality
squeeze-prone · 86
live supply-pressure model
Supply factor
negative gap pressure
detector reason
Supply factor
very tight float
detector reason
Supply factor
heavy float rotation
detector reason
Supply factor
nano-cap supply profile
detector reason
This estimates whether a gap is clean, squeeze-prone, mixed, or supply-heavy using float, float rotation, short interest, market cap, split risk, and live volume. Registered resale/ATM exhaustion is a planned deeper parser layer.
2026-09-11 14:55 ETSignalSilexion Therapeutics Corp Ordinary Shares is down 18.1%, at 0.35, on $774.4K traded, 0.58× float rotation. Score 74. Primary driver: 58.1% float rotation. Supply intelligence: squeeze-prone · 86.
2026-08-148-KItem 2.02 — Results of operations and financial condition; Item 9.01 — Financial statements and exhibits SEC
2026-08-138-KItem 1.01 — Entry into a material definitive agreement; Item 8.01 — Other events +1 more SEC
2026-05-29Split1-for-10 reverse split logged
2026-05-13 08:00 ETFDA / ClinicalSilexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center News
2025-12-02 08:00 ETFDA / ClinicalSilexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer News
2025-11-12 09:00 ETFDA / ClinicalSilexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update News
2025-09-11 07:00 ETFDA / ClinicalSilexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration News
Latest detector signalscore 74